Long-Term Evaluation of Glucose Homeostasis in a Cohort of HAART-Treated HIV-Infected Children
Authors:
- Alessandra ViganòAVAlessandra Viganò
- Paolo BrambillaPBPaolo Brambilla
- Gian V. ZuccottiGian V. Zuccotti
- Giorgio BedogniGBGiorgio Bedogni
- 1 January 2009
- journal article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 29 (2) , 101-109
Abstract
Background and objectives: Few and mainly cross-sectional studies of glucose homeostasis are available in HIV-infected children treated with highly active antiretroviral therapy (HAART). The aim of the present study was to describe a 4-year course of glucose homeostasis in a cohort of HAART-treated children and adolescents, using glucose and insulin levels during an oral glucose tolerance test (OGTT) as outcome measures. In addition, we investigated possible risk factors, both related and unrelated to antiretroviral therapy, associated with insulin resistance. Methods: We assessed glucose metabolism yearly for 4 consecutive years in 37 HIV-infected children receiving a protease inhibitor (PI)-based HAART regimen containing lamivudine/stavudine plus indinavir or ritonavir or nelfinavir or a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen containing lamivudine/tenofovir/efavirenz. Generalized estimating equations were used to evaluate the relationship between the loge-transformed area under the serum concentration-time curve (AUC) of insulin during OGTT and antiretroviral therapy, controlling for time, sex, baseline age, puberty, body mass index and CD4+ T cells percentage. Results: Ritonavir-unboosted PI-based HAART regimens were administered to most children at baseline; however, their use decreased during follow-up in favour of an NNRTI-based regimen. The nelfinavir/lamivudine/stavudine (regression coefficient = −0.69, p < 0.05) and efavirenz/lamivudine/tenofovir (regression coefficient = −0.93, p < 0.05) regimens, but not the ritonavir/lamivudine/stavudine regimen, were negatively associated with loge-transformed insulin AUC compared with indinavir/lamivudine/stavudine. Puberty was positively associated with loge-transformed insulin AUC. Conclusions: This 4-year prospective study of HAART-treated HIV-infected children shows that: (i) the nelfinavir/lamivudine/stavudine and the efavirenz/ lamivudine/tenofovir regimens but not the ritonavir/lamivudine/stavudine regimen were associated with higher insulin sensivity, i.e. lower insulin AUC, compared with indinavir/lamivudine/stavudine; (ii) the treatment switched substantially in favour of NNRTI from the third year on and this change was associated with an improvement in insulin sensitivity compared with the previous HAART-based regimens; and (iii) puberty is a primary determinant of insulin sensitivity.Keywords
This publication has 32 references indexed in Scilit:
- Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected PatientsDiabetes Care, 2008
- Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV StudyAIDS, 2007
- Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adultsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Fat Distribution in Women With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Methods for clinical assessment of insulin sensitivity and β-cell functionBest Practice & Research Clinical Endocrinology & Metabolism, 2003
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes MellitusDiabetes Care, 2003
- Switching to Nevirapine Decreases Insulin Levels but Does Not Improve Subcutaneous Adipocyte Apoptosis in Patients with Highly Active Antiretroviral Therapy–Associated LipodystrophyThe Journal of Infectious Diseases, 2001
- Metabolic Abnormalities in HIV Type 1-Infected Children Treated and Not Treated with Protease InhibitorsAIDS Research and Human Retroviruses, 2001
- Disorders of Glucose Metabolism in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2000
- Impact of Switching from Human Immunodeficiency Virus Type 1 Protease Inhibitors to Efavirenz in Successfully Treated Adults with LipodystrophyClinical Infectious Diseases, 2000